VIENNA — The need for renal replacement therapy has stabilized in many parts of the Western world, new registry data show. "There was a continuous increase in the incidence of renal replacement therapy from the 1980s until the early 2000s, and ... General Medicine eJournal, 4 weeks ago
Renal Disease Treatments: Products and Therapies - Global Information Inc, 2 days ago
Global Continuous Renal Replacement Therapy (CRRT) Market 2016 - Industry Forecast to 2025 for the $1.6 Billion Market - 4 Traders, 4 weeks ago
Share this content: Early initiation of renal replacement therapy (RRT) significantly improves 90-day survival among critically ill patients with acute kidney injury (AKI), researchers reported at the European Renal Association-European Dialysis ...Renal & Urology News, 1 month ago Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit New England Journal of Medicine, 1 month ago Risk Factors ID'd for Early Mortality After Starting CRRT Renal & Urology News, 4 weeks ago Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients New England Journal of Medicine, 4 weeks ago
Prognosis of extremely severe lactic acidosis in metformin-treated patients with septic shock: continuous (?) renal replacement therapy in the spotlight!
K.Doenyas-Barak , I.Beberashvili and S.Efrati The role of RRT in the treatment of lactic acidosis in general, and in metformin-associated lactic acidosis (MALA) in particular, has been the subject of several trials. Due to the low molecular ...Critical Care, 1 month ago
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary ...Minyanville, 2 days ago Modelling the Cost-Effectiveness of Delaying End-Stage Renal Disease Karger.com, 2 weeks ago Mirna Therapeutics Reports First Quarter 2016 Financial Results And Program Updates TheStreet.com, 1 month ago ROCKWELL MEDICAL : Announces Multiple International Trademark Approvals for Triferic® 4 Traders, 1 month ago
Baxter's 1Q16 Earnings Beat Estimates, Post Improved Margins ( Continued from Prior Part ) 1Q16 performance Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$898 million, or ~38%, came from Baxter's Renal ...Yahoo! Finance UK and Ireland, 1 month ago
More from: , Yahoo! Finance...and 1 other sources
Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients
Read more ›› By: Nasdaq / GlobenewsWire - 13 Jun 2016 Related companies: Immunomedics, Inc. Lifestyle Intervention Achieves Increased Reduction in A1C After Six Months for African Americans with Type 2 Diabetes NEW ORLEANS, June 12, ...USA Life Sciences Database, 1 week ago Adamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson's Disease and Movement Disorders International Business Times, 4 days ago ADAMAS PHARMACEUTICALS : Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson's Disease and Movement Disorders 4 Traders, 4 days ago
Monitoring of Potential Safety Events and Vital Signs during Active Mobilization of Patients Undergoing Continuous Renal Replacement Therapy in a Medical Intensive Care Unit
Background/Aims: This study aims to evaluate potential safety events and vital sign changes during active mobilization physical therapy (PT) in critically ill patients undergoing continuous renal replacement therapy (CRRT). Methods: A retrospective ...Blood Purification, 1 month ago
Biotech Forum Daily Digest: The Biotech Rally Continues, Relypsa Gets Some Traction, Exelixis Living Up To Its Promise.
Biotech continues to build on the strength it demonstrated last week and biotech indices surged over two percent on Tuesday after a solid start to the week on Monday. Monday's rise was mainly led by the small cap names in the sector, probably helped ...Seeking Alpha, 1 month ago
Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent
Updated Findings from KEYNOTE-012 for KEYTRUDA® Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Metastatic Head and Neck Cancer Merck ( NYSE:MRK ), known as MSD outside the United States ...BioSpace, 2 weeks ago MERCK : Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer 4 Traders, 2 weeks ago Merck's KEYTRUDA® pembrolizumab Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in... 4 Traders, 2 days ago Merck's KEYTRUDA®(pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Enhanced Online News, 1 week ago
) - During the past decade, the chronic kidney disease (CKD) rate has risen by more than 25% in the U.S. BCC Research reveals in its new report that the predominant growth drivers of the renal disease market include an aging population, increasing ...BioSpace, 3 days ago
More from: , Financial Buzz...and 3 other sources
on your WebpageAdd Widget >Get your members hooked!